POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
ASCO
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
ASCO
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Chemotherapy Induced Profound Neutropenia (PN) in Patients (pts) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim(Peg) Combination versus (vs) Peg Alone. Final Phase 3 Results from PROTECTIVE-2
(BPI-2358-106)
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Clinical Trial Testing Superiority of Combination Plinabulin and Pegfilgrastim vs Pegfilgrastim Alone in Patients with Breast Cancer Treated with High Febrile Neutropenia Risk Chemotherapy: Final Results of the Phase 3 Chemotherapy-Induced Neutropenia Prevention Trial (PROTECTIVE-2)
ISSCR
06.30.2020
ISSCR 2020 Virtual
A Single IV Dose of Plinabulin Induces Sustained Mobilization of CD34+ Cells in Humans Through A Mechanism of Action Independent From G-CSF or CXCR4 and Without Causing Bone Pain or Thrombocytopenia
ASCO
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
ASCO
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Chemotherapy Induced Profound Neutropenia (PN) in Patients (pts) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim(Peg) Combination versus (vs) Peg Alone. Final Phase 3 Results from PROTECTIVE-2
(BPI-2358-106)
PUBLICATIONS
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
Chem
11.14.2019
Chem
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes
Cell Reports
09.24.2019
Cell Reports
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-Tumor Responses
Investigational New Drugs
02.16.2011
Investigational New Drugs
Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
Chem
11.14.2019
Chem
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes